ResMed Inc. (NYSE:RMD) Director Richard Sulpizio sold 24,390 shares of the company’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $73.85, for a total transaction of $1,801,201.50. Following the completion of the sale, the director now owns 28,819 shares of the company’s stock, valued at approximately $2,128,283.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Richard Sulpizio also recently made the following trade(s):

  • On Thursday, June 22nd, Richard Sulpizio sold 65,887 shares of ResMed stock. The shares were sold at an average price of $77.82, for a total transaction of $5,127,326.34.

ResMed Inc. (NYSE:RMD) traded down 0.08% during trading on Friday, reaching $72.56. The company’s stock had a trading volume of 421,738 shares. The company has a market cap of $10.32 billion, a P/E ratio of 30.23 and a beta of 0.83. ResMed Inc. has a 12 month low of $56.59 and a 12 month high of $79.63. The stock’s 50-day moving average is $76.66 and its 200 day moving average is $72.21.

ResMed (NYSE:RMD) last posted its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 EPS for the quarter, topping the consensus estimate of $0.75 by $0.02. The company had revenue of $556.69 million during the quarter, compared to the consensus estimate of $557.68 million. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.74 earnings per share. On average, equities analysts forecast that ResMed Inc. will post $3.03 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 21st. Stockholders of record on Thursday, August 17th will be given a dividend of $0.35 per share. The ex-dividend date is Tuesday, August 15th. This is an increase from ResMed’s previous quarterly dividend of $0.33. This represents a $1.40 annualized dividend and a dividend yield of 1.93%. ResMed’s payout ratio is presently 54.77%.

WARNING: “ResMed Inc. (NYSE:RMD) Director Sells $1,801,201.50 in Stock” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/resmed-inc-nysermd-director-sells-1801201-50-in-stock/1473808.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RMD. Commerzbank Aktiengesellschaft FI boosted its position in ResMed by 0.3% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 5,238 shares of the medical equipment provider’s stock valued at $377,000 after buying an additional 14 shares during the period. Sawtooth Solutions LLC boosted its position in ResMed by 1.6% in the second quarter. Sawtooth Solutions LLC now owns 3,167 shares of the medical equipment provider’s stock valued at $247,000 after buying an additional 49 shares during the period. Morgan Dempsey Capital Management LLC boosted its position in ResMed by 2.3% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,189 shares of the medical equipment provider’s stock valued at $158,000 after buying an additional 50 shares during the period. Intrust Bank NA boosted its position in ResMed by 1.0% in the first quarter. Intrust Bank NA now owns 7,101 shares of the medical equipment provider’s stock valued at $511,000 after buying an additional 73 shares during the period. Finally, Pacer Advisors Inc. boosted its position in ResMed by 3.0% in the first quarter. Pacer Advisors Inc. now owns 2,699 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 79 shares during the period. Institutional investors and hedge funds own 60.68% of the company’s stock.

A number of research firms recently commented on RMD. Zacks Investment Research upgraded shares of ResMed from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Credit Suisse Group cut shares of ResMed from an “outperform” rating to a “neutral” rating in a research report on Wednesday, August 2nd. BMO Capital Markets upped their price objective on shares of ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a research report on Wednesday, August 2nd. Citigroup Inc. upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 2nd. Finally, Needham & Company LLC restated a “sell” rating on shares of ResMed in a research report on Wednesday, August 2nd. Four research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $65.63.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.